FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely to oncohaematology, and can be used to monitor the effectiveness of the anti-tumour treatment of patients with multiple myeloma. For this purpose the concentration of free light chains of immunoglobulins is determined before and 24 hours after finishing the treatment course. In case of a 60% reduction of the concentration, the performed treatment is considered to be effective, in case the reduction of the concentration is 60% and lower - ineffective.
EFFECT: application of the claimed method makes it possible to obtain data about the treatment effectiveness in short terms, which increases the probability of remission achievement due to individual adequate selection of a scheme for anti-tumour treatment.
5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREVENTING RENAL DAMAGE IN PATIENTS WITH A PRIMARILY IDENTIFIED SECRETING MULTIPLE MYELOMA | 2017 |
|
RU2652082C1 |
| METHOD OF CHEMOTHERAPY EFFICIENCY PREDICTION IN PATIENTS WITH MALIGNANT GLIOMA | 2007 |
|
RU2341794C1 |
| METHOD FOR DETECTION OF PRIMARY REFRACTORY FORM OF MULTIPLE MYELOMA AT THE DISEASE ONSET | 2020 |
|
RU2749612C1 |
| METHOD OF TREATING T-CELL LYMPHOMAS AND KAPOSIS'S SARCOMA | 2009 |
|
RU2401671C1 |
| METHOD FOR PREDICTION OF CLINICAL COURSE OF AUTOIMMUNE PEMPHIGUS | 2010 |
|
RU2429482C1 |
| METHOD OF DETERMINING THE RISK GROUP FOR PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY PLASMACYTOMA | 2022 |
|
RU2801094C1 |
| METHOD OF ONCOLOGICAL PATIENTS TREATMENT | 2007 |
|
RU2341306C1 |
| METHOD OF TREATING PATIENTS WITH MULTIPLE MYELOMA COMPLICATED BY DOUBLE REFRACTORINESS WITH HELP OF NATURAL KILLER-CELL ADAPTIVE IMMUNOTHERAPY | 2024 |
|
RU2836995C1 |
| METHOD OF TEACHING MALIGNANT BRAIN GLIOMA | 2009 |
|
RU2402360C1 |
| METHOD FOR PREDICTION OF CHEMOTHERAPEUTIC EFFECTIVENESS IN PATIENTS WITH MALIGNANT NEW GROWTHS OF EPITHELIAL TISSUES | 2013 |
|
RU2542505C1 |
